Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its […]
Over US$ 550 million raised by portfolio companies in 2021 IO Biotech IPO on US NASDAQ Forendo Pharma acquired for nearly US$ 1 billion Muna launched with world-leading science to advance latest scientific breakthroughs in neuroscience Adcendo raised US$ 60 million Series A to deliver next-generation Antibody-Drug Conjugates Hemab raised US$ 50 million Series A to […]
Funds will be used to support the development of pioneering mammary biotechnology to bring a novel infant feeding option to market that better meets infants’ nutritional needs Syndicate includes leading clean tech and food tech investors Copenhagen, Denmark – 20 October 2021 – Novo Holdings, a leading international life science investor, today announces it has led […]
Novo Holdings’ 2020 result is based on a strong performance from both the Investment Portfolio and the Novo Group companies (Novo Nordisk and Novozymes). “2020 was a very satisfactory year for Novo Holdings, despite the unprecedented challenges of the COVID-19 crisis. Our income and investment returns are once again well balanced, with strong contributions […]
European investors continue actively investing in healthcare. The survey held in May 2020 includes responses from 24 of the most influential European VCs, investing approximately EUR 15.5 billion in aggregate in the Healthcare sector.